VivoSeq
Immunology

Psoriasis

452

Pipeline Programs↗

122

Active Trials↗

149

Companies Involved↗

Psoriasis is a highly competitive landscape with 452 programs across 149 companies. The most active players are Boston Pharmaceuticals, Tianjin Ever Union Biotechnology Co., Ltd., Arxx Therapeutics. 57 therapies are approved with 99 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

93/100

Pipeline Velocity

63/100

Mech. Concentration

11/100

Completion Rate

90/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Boston Pharmaceuticals

2 programs

Phase 1T

Tianjin Ever Union Biotechnology Co., Ltd.

2 programs

Phase 1A

Arxx Therapeutics

1 program

Phase 1A

Azora Therapeutics Australia Pty Ltd

1 program

Phase 1P

Prothena Biosciences Limited

1 program

Phase 1N

Nektar Therapeutics

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

514 of 560 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody275%Protein / enzyme92%Cell therapy4<1%Peptide3<1%Vaccine3<1%

Small molecule leads; the ring shows all 560 classified programs, each share of the total. Modality classified for 99% of 606 pipeline programs.

Analysis

Trial Status

1,066

clinical trials

Completed797 · 75%
Terminated61 · 6%
Recruiting56 · 5%
Unknown status56 · 5%
Not yet recruiting31 · 3%
Active, not recruiting31 · 3%
Other34 · 3%

Clinical Trials

Trial Activity

1066 trials

Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.
Recruiting·UUniversity Medical Center Groningen·Phase 1·NCT05725876·56 enrolled
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
Recruiting·—·Phase 1·NCT07337434·106 enrolled
Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis.
Recruiting·MMae Fah Luang University·Phase 2·NCT07410793·28 enrolled
Taltz in Combination With Enstilar for Psoriasis
Recruiting·PPsoriasis Treatment Center of Central New Jersey·Phase 4·NCT04372277·25 enrolled
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
Recruiting·—·Phase 2·NCT06742333·40 enrolled
A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
Recruiting·ZZai Lab (Hong Kong), Ltd.·Phase 2·NCT06380907·250 enrolled
A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis
Recruiting·ZZhejiang Wenda Pharma Technology LTD.·Phase 2·NCT06912165·140 enrolled
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2·NCT07251998·172 enrolled
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT07256015·200 enrolled
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
Recruiting·FFirst Hospital of China Medical University·N/A·NCT06696417·1,516 enrolled
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
Recruiting·HHuabo Biopharm Co., Ltd.·Phase 3·NCT06477237·400 enrolled
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
Recruiting·SSingapore General Hospital·Phase 4·NCT04537689·40 enrolled
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Recruiting·PPsoriasis Treatment Center of Central New Jersey·Phase 4·NCT03827876·30 enrolled
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
Recruiting·AArcutis Biotherapeutics, Inc.·Phase 1·NCT07340216·16 enrolled
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
Recruiting·IInventisBio Co., Ltd·Phase 3·NCT07130604·390 enrolled
Page 1 of 72

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)